Answers are grounded in this paper and cite their sources.
Introduction To evaluate the effects of a new lubricating, antioxidant solution (VisuEvo ® ) on dry eye disease (DED) in patients undergoing cataract surgery. Methods Patients requiring cataract surgery with either healthy ocular surface or mild DED (tear break-up time, TBUT > 7, Schirmer I test > 15 mm/5 min) were enrolled in this multicenter, open-label, randomized, prospective study. Scheduled visits were 2 weeks before surgery (screening), day of surgery (V0), week 1 (V1), and 2 (V2) after surgery. VisuEvo ® was self-administered three times daily for the whole study duration (group A); the control group (group B) had no tear substitute administration. The primary endpoint was the change in TBUT over time; the secondary endpoints were changes in Ocular Surface Disease Index (OSDI), ocular surface staining, the Schirmer I test, and osmometry. Results A total of 45 patients were included (group A, 23; group B, 22; age 74 ± 8 years). At the screening, TBUT was similar between the groups (group A, 8.5 ± 1.8 s; group B, 7.8 ± 0.7, p = 0.11). At the scheduled visits, TBUT increase vs screening visit was significantly higher in group A: +1.2 s at V0, +1.4 s at V1, and +1.9 s at V2 ( p < 0.01). Also, OSDI was significantly lower in group A at V0, V1, and V2 ( p < 0.027). After surgery, corneal staining was absent in 65–78% of group A compared with 54–59% in group B. The two groups did not show any significant differences of osmometry and the Schirmer I test. Conclusions The ocular surface was more protected and quickly restored from surgery when VisuEvo ® was used from 2 weeks preoperatively to 2 weeks postoperatively. Trial registration ClinicalTrials.gov identifier, NCT03833908
No takes yet. Share an insight, caveat, or question.
Fogagnolo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: